Pharmacogenomic study of the effects of saxagliptin on glucose control and hypoglycemic events

Abstract Background Saxagliptin is a DPP-4 inhibitor widely used to manage type 2 diabetes, though genetic contributors to variability in response remain unclear. This study aimed to identify genetic variants associated with the efficacy and safety of saxagliptin using genome-wide association studie...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marc-Olivier Pilon, Simon de Denus, Géraldine Asselin, Marc-André Legault, Hervira Brenda Ngongang Kwandjang, Amina Barhdadi, Louis-Philippe Lemieux Perreault, Diane Valois, Ian Mongrain, Carolina Haefliger, Dirk S. Paul, Ewan R. Pearson, Jean-Claude Tardif, Marie-Pierre Dubé
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2026-03-01
coleção:	BMC Medical Genomics
Assuntos:	Pharmacogenomics Saxagliptin Genome-wide association studies HbA1c Hypoglycemic event
Acesso em linha:	https://doi.org/10.1186/s12920-026-02348-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!